Last reviewed · How we verify
RETEPLASE
At a glance
| Generic name | RETEPLASE |
|---|---|
| Modality | Enzyme |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke (NA)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer (PHASE3)
- Intravenous Thrombolysis and NOAC (PHASE3)
- Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months (PHASE3)
- Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality (PHASE3)
- Endovascular Stroke Treatment And Reteplase Protocol (PHASE2)
- A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RETEPLASE CI brief — competitive landscape report
- RETEPLASE updates RSS · CI watch RSS